Charité - Universitätsmedizin Berlin

Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis (2016) Witte T, Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries P, Bannert B, et al. Conference contribution INTER SPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS (2016) Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries PM, Bannert B, Becker K, et al. Conference contribution DISEASE PROGRESSION IN 282 PATIENTS WITH UNDIFFERENTIATED SSC - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLERODERMA (2016) Moinzadeh P, Blank N, Siegert E, Henes J, Susok L, Distler J, Juche A, et al. Conference contribution ANTI-MODIFIED PROTEIN ANTIBODY RESPONSE PATTERN INFLUENCES THE RISK FOR DISEASE RELAPSE IN RHEUMATOID ARTHRITIS PATIENTS TAPERING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (2016) Figueiredo C, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Single Deepest Vertical Pocket or Amniotic Fluid Index as Evaluation Test for Predicting Adverse Pregnancy Outcome (SAFE Trial): A Multicenter, Open-Label, Randomized Controlled Trial EDITORIAL COMMENT (2016) Kehl S, Schelkle A, Thomas A, Puhl A, Meqdad K, Tuschy B, Berlit S, et al. Journal article, Editorial Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, et al. Conference contribution Psychooncological counseling and treatment as part of the Comprehensive Cancer Center (CCC): Multicenter study to detect the psycho-oncological needs, indications and using (2016) Buettner-Teleaga A, Weis J, Goerling U, Hornemann B, Erim Y, Beckmann M, Senf B, et al. Conference contribution Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution